Safe Orthopaedics SAの推定成長EPS Q/QはN/Aです。
期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Ãragny-sur-Oise, France.